10:42 AM EDT, 08/13/2025 (MT Newswires) -- Creative Medical Technology ( CELZ ) said Wednesday the US Food and Drug Administration has granted fast track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease, a major cause of chronic lower back pain and disability.

The designation enables the company to benefit from quicker FDA interactions, rolling Biologics License Application submissions, and eligibility for priority review, Creative Medical Technology ( CELZ ) said.

The company's shares were up nearly 0.2% in recent Wednesday trading.